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Variants near CHRNA3/5 and APOE have
age- and sex-related effects on human lifespan
Peter K. Joshi1, Krista Fischer2, Katharina E. Schraut1,3, Harry Campbell1, To˜nu Esko2,4,5,6 & James F. Wilson1,7
Lifespan is a trait of enormous personal interest. Research into the biological basis of human
lifespan, however, is hampered by the long time to death. Using a novel approach of
regressing (272,081) parental lifespans beyond age 40 years on participant genotype in a
new large data set (UK Biobank), we here show that common variants near the
apolipoprotein E and nicotinic acetylcholine receptor subunit alpha 5 genes are associated
with lifespan. The effects are strongly sex and age dependent, with APOE e4 differentially
inﬂuencing maternal lifespan (P¼4.2 10 15, effect  1.24 years of maternal life per
imputed risk allele in parent; sex difference, P¼0.011), and a locus near CHRNA3/5
differentially affecting paternal lifespan (P¼4.8 10 11, effect 0.86 years per allele; sex
difference P¼0.075). Rare homozygous carriers of the risk alleles at both loci are predicted
to have 3.3–3.7 years shorter lives.
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B
eing alive is the simplest, summary measure of overall
health. Thus the genomics of longevity offer the prospect of
illuminating system-wide components of health that are not
related to disease and biological systems involved in both frailty
and healthy ageing. Genetic factors are suggested to account for
up to 16–25% of the variation in long-livedness1,2. However,
whereas studies in model organisms have revealed signalling
pathways with profound inﬂuences on lifespan3, only one locus
has consistently been associated with human survival: APOE4–6.
Efforts to discover additional age-related genetic loci are impeded
by difﬁculties in recruiting very large prospective cohorts with
lifespan and genomic data that are required to give sufﬁcient
power to detect the expected small effects associated with this
complex trait. Although many population cohorts can capture
family history, subjects recruited in middle age will have aged or
deceased parents. UK Biobank7 (UKB) is a particularly rich
resource in this context: half a million people were recruited aged
40–69 years and genome-wide genotypes are presently available
for 152,732 subjects. The ﬁrst genetic association analysis in UKB
for lung function has recently been published8. Hundreds of
thousands of parents of UKB participants were deceased at the
time of baseline measurements. The use of phenotyped (but not
genotyped) relatives of subjects who have been genotyped to
conduct association analyses between phenotype and
probabilistically inferred genotype, generalizes the approach of
Wacholder et al.9 from Mendelian traits to quantitative traits and
provides a step change in power, applicable to all late onset
conditions, where direct genotyping may be problematic. Here we
use this approach to show that common variants near the
apolipoprotein E and nicotinic acetylcholine receptor subunit
alpha 5 genes are associated with lifespan in a sex- and age-
dependent manner. The APOE e4 allele differentially inﬂuences
maternal lifespan (P¼ 4.2 10 15, effect  1.24 years of
maternal life per imputed risk allele in parent), and a locus
near CHRNA3/5 differentially affects paternal lifespan
(P¼ 4.8 10 11, effect  0.86 years per allele). The B0.3% of
Europeans who are homozygous carriers of the risk alleles at both
loci are predicted to have 3.3–3.7 years shorter lives. Thus the
major genetic determinants of lifespan are both very pleiotropic
disease susceptibility genes.
Results
Discovery cohort. In the discovery phase genome-wide associa-
tion (GWAS), using rank-normalized Martingale residuals of
survivorship for 116,425 UKB subjects of unambiguous British
genetic ancestry, we discovered 35 single nucleotide polymorph-
isms (SNPs) (Supplementary Table 1) with a P value o10 6 for
association in meta-analysis of paternal and maternal lifespans.
However, only two loci reached genome-wide signiﬁcance
(Po5 10 8), on chromosome 15 and 19 (Fig. 1). Several SNPs
are associated with lifespan in each region, the most signiﬁcant
being rs429358 in APOE at chromosome 19q13 and rs10519203
in a locus including HYKK, PSMA4, CHRNA5, CHRNA3 and
CHRNB4 at chromosome 15q24 (Fig. 2). However, the chromo-
some 15 association, which we refer to hereafter as CHRNA3/5,
appears much stronger in men than in women and conversely the
APOE association is much stronger in women than men (Fig. 1).
Q–Q plots (Supplementary Fig. 1a–c) show no inﬂation, sug-
gesting that there are no issues with relatedness, population
structure or other confounding factors. Conditioning on both
sentinel SNPs removed all other signals in these regions and the
distribution of P values appeared consistent with chance
(Supplementary Fig. 1d); there was also no evidence of associa-
tions at FOXO3 and 5q33, recently associated with nonagenarian
subjects6,10.
Under the full Cox model in the discovery cohort (that is,
genotype effect ﬁtted simultaneously with other covariates), the
per allele hazard ratios across both parental sexes were 1.115
(P¼ 6.29 10 19) for the C allele at rs429358 and 1.057
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Figure 1 | Genome-wide association with parental lifespan. Manhattan plots are presented for the discovery analysis in genetically British individuals (a)
for fathers, (b) for mothers, (c) for meta-analysis of parents. In each case the trait is the Martingale residuals of the Cox proportional hazards model of
parental lifespan. rs429358 and rs10519203 explain, respectively, 0.026/0.068% and 0.042/0.012% of the variance of the Martingale residuals in
fathers/mothers.
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(P¼ 1.95 10 13) for the G allele at rs10519203 (Table 1).
However, the effect sizes in each parental sex differed strongly.
The survival reduction due to rs429358 at APOE was 0.79 and
1.24 years per risk allele and due to rs10519203 near CHRNA3/5
was 0.86 and 0.60 years in fathers and mothers, respectively
(Table 1; the P value for a difference in hazard ratio between the
sexes was 0.011 for rs429358 and 0.073 for rs10519203; two-sided
t-test of contrast). Bivariate analysis also showed that association
is mediated through rs429358, not rs4420638 near TOMM40 (in
high linkage disequilibrium, r2¼ 0.71): bivariate loge hazard ratio
(±1 s.e.) for mothers in the discovery cohort were 0.067
(±0.017) and 0.005 (±0.018), respectively.
Replication. We sought replication in three data sets, two from
non-genetically British sub-cohorts of UKB using parental
lifespans, and one from the Estonian Biobank using participant
survival. Hazard ratios in the three replication cohorts were all
directionally consistent, and fell within two s.e’.s of the estimate
in the discovery cohort. After meta-analysis of the three repli-
cation studies (not including the discovery cohort), the P values
for association were 0.0020 for rs429358 in APOE and 6.8 10 6
for rs10519203 near CHRNA3/5, and estimated effect sizes were
again consistent with the discovery cohort (Table 1). In an overall
meta-analysis of the discovery and replication sets, P values were
1.15 10 20 for rs429358 and 1.8 10 17 for rs10519203.
Age-dependent effects. To investigate whether effects varied by
age at death, we compared allele hazard ratios at ages-of-death of
40–75 and over 75, very broadly the mean age across men and
women, alive and dead. The estimated hazard ratio for rs429358
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Figure 2 | Locus zoom plots for the two robust associations with parental lifespan. (a) CHRNA3/5 region and paternal lifespan, (b) APOE region and
maternal lifespan.
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in APOE was larger at older ages: 1.09 in younger mothers and 1.20
in older mothers (the more affected sex), with 0.2 life years lost before
age 75 years, but 1.1 years beyond it (Table 2). The estimated hazard
ratio for rs10519203 near CHRNA3/5 was smaller at older ages: 1.10
in younger fathers and 1.03 in older fathers (the more affected sex),
with 0.5 life years lost before age 75 years, but only 0.1 years beyond
it. The P value for the difference in log hazard ratios at younger and
older ages, iso0.006 in the more affected sex for both variants, and
although directionally suggestive, is not signiﬁcant (P40.05) for the
less affected sex for both alleles, (two sided t-test of contrast in effect
size, in both cases).
The effect sizes are relatively large, conferring between 0.6–1.2
years less life per allele (by sex) for both loci. Homozygous
carriers of the risk alleles at both loci (around 0.27% of the
population) are predicted to have 3.3–3.7 years shorter lives
compared to homozygotes carrying the protective variants.
Discussion
We have shown that common variants at two loci are associated
with lifespan, and these effects are strongly age- and sex-related.
The APOE* e4 allele increases in particular the risk of mortality
for older females, whereas a variant near CHRNA3/5 has stronger
effects on young to middle-aged men.
Apolipoprotein E is a receptor-binding ligand on the surface of
chylomicrons, intermediate and low-density lipoprotein particles,
and is involved in uptake and redistribution of lipids. It is widely
expressed, most strongly in the liver, brain and retina. The signal
we observe is driven by rs429358, a non-synonymous Cys112Arg
variant, which deﬁnes the e4 allele and which has not previously
been shown to be the causal variant inﬂuencing lifespan. Previous
ﬁndings of association of longevity with rs4420638 near
TOMM40 (refs 5,6), appear to arise from linkage disequilibrium
with rs429358 (not genotyped in the prior work). The APOE
Table 1 | Association of paternal and maternal lifespan in the UK Biobank discovery analysis.
Population Parent Lives Deaths Beta HR s.e. P value Years
rs429358, chr19:45411941 C allele APOE
UKB: Genet. British Father 73,100 55,568 0.0805 1.084 0.0165 1.08 10 6 0.79
UKB: Genet. British Mother 75,576 45,254 0.1426 1.153 0.0182 4.22 10 15  1.24
Discovery Both 148,676 100,822 0.1086 1.115 0.0122 6.29 10 19
P sex effect 0.011
UKB: declared British Both 20,874 13,979 0.0341 1.035 0.0337 0.31
UKB: other origins Both 11,771 7,483 0.1146 1.121 0.0488 0.0189
Estonian Biobank Offspring 5,196 1,499 0.1190 1.120 0.0560 0.034
Replication 37,841 22,961 0.0716 1.074 0.0248 0.0020
Overall 186,517 123,783 0.1014 1.107 0.0110 1.15 10 20
rs10519203, chr15:78814046 G allele CHRNA3/5
UKB: Genet. British Father 111,025 85,182 0.0675 1.070 0.0103 4.83 10 11 0.86
UKB: Genet. British Mother 115,003 69,796 0.0403 1.041 0.0113 3.84 104 0.60
Discovery Both 226,028 154,978 0.0552 1.057 0.0076 1.95 10 13
P sex effect 0.075
UKB: declared British Both 31,349 21,309 0.0675 1.070 0.0206 0.0010
UKB: other origins Both 14,223 9,308 0.0516 1.053 0.0335 0.124
Estonian Biobank Offspring 5,196 1,499 0.1010 1.130 0.0390 0.0100
Replication 50,768 32,116 0.0695 1.072 0.0160 6.82 10 6
Overall 276,796 187,094 0.0579 1.060 0.0069 1.82 10 17
P values are given for the discovery analysis allele dose effect for the sentinel SNP at each locus, separately for maternal and paternal lifespans, and the meta-analysis of both. Discovery was carried out in
the genetically British subset of UKB, with replication for parental lifespans in (a) the self-declared British who did not meet the strict UKB deﬁnition of genetically British (declared British), (b) UKB
participants of other origins (declared and genetic) who were analysed as separate ethnic groups and then meta-analysed and (c) with participant survival in participants in the Estonian Biobank. The
effects in UKB reﬂect imputation of 0.5 parental allelic doses from 1 offspring allelic dose. Beta is the effect size from the full Cox model, HR is hazard ratio, years gives the reduction in lifespan in years for
a (parental generation) individual carrying one copy of the variant. The number of observations for rs429358 is much lower than for rs10519203, because this locus was not included in the UK BiLEVE
array used to genotype 50,000 subjects, nevertheless it was the most signiﬁcant variant in the region. The chromosome co-ordinates use GRCh37. Genet. British are genetically British.
Table 2 | Associations with lifespan are age-dependent.
Parent Age range Lives Deaths Beta HR s.e. P value Years
Variant rs429358
Father 40–75 73,100 33,393 0.0752 1.0588 0.0212 7.03 10 3 0.30
Father 75þ 35,778 24,086 0.1147 1.1216 0.0252 5.34 10 6 0.65
Mother 40–75 75,576 20,780 0.0858 1.0896 0.0268 0.0013 0.19
Mother 75þ 46,365 25,846 0.1847 1.2028 0.0241 1.72 10 14  1.13
Variant rs10519203
Father 40–75 111,025 51,984 0.0924 1.0968 0.0131 1.66 10 12 0.47
Father 75þ 53,244 36,139 0.0321 1.0327 0.0158 0.043 0.16
Mother 40–75 115,003 32,758 0.0565 1.0581 0.0165 6.24 104 0.26
Mother 75þ 69,620 39,201 0.0292 1.0296 0.0152 0.055 0.23
P values are given for the discovery analysis of parental allelic dose effect for the sentinel SNP at each locus, separately for maternal and paternal lifespans and younger (40–75) and older (75þ ) ages.
Beta is the effect size from the full Cox model, HR is hazard ratio, years gives the reduction in lifespan in years for a (parental generation) individual carrying one copy of the variant.
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locus and in some cases speciﬁcally the e4 allele have been
associated with an array of age-related conditions and traits,
including Alzheimer’s dementia11, age-related cognitive decline12,
total and low-density lipoprotein cholesterol and triglycerides13,
C-reactive protein14, coronary disease risk15 as well as
centenarianship16 and survival to 90 years5. The association we
observe with lifespan is potentially due to the combined impact of
the cognitive and cardiometabolic effects on mortality. There has
been debate as to whether APOE primarily inﬂuences mortality
across the spectrum of ages at death (frailty) or survival to old age
(longevity). In stratiﬁed analyses for parental deaths before and
after 75 years, we see a much stronger effect of e4 on dying after
75 years, for both mothers and fathers, providing strong
additional evidence for an effect on survival to 490 years4–6.
Whereas APOE inﬂuences the lifespan of fathers and mothers,
we observe robust evidence for a stronger effect in mothers. No
sex-speciﬁcity has been reported for the effects on lipids, but there
is evidence for a stronger effect of APOE on Alzheimer’s risk in
females17. The effect on cognitive function is also much stronger
in females18 and longitudinal analyses conﬁrm the mortality
effect is strongest for female lifespans of about 70–95 years19.
Smoking is the single-most important cause of premature death in
the developed world, increasing the risk of many diseases including
lung cancer, coronary heart disease, chronic obstructive pulmonary
disease and emphysema. The CHRNA5-CHRNA3-CHRNB4 locus
encodes various nicotinic acetyl choline receptor subunits, ion
channels that mediate fast signal transduction at synapses. Various
SNPs in our associated interval have been associated with smoking
quantity20, nicotine dependence20, lung cancer21, chronic obstructive
pulmonary disease22, peripheral arterial disease20, alcohol
dependence (independent of smoking status23) and
schizophrenia24. The region is modestly associated (P¼ 1 10 4)
with airway obstruction in never smokers25, and the effects on lung
cancer and chronic obstructive pulmonary disease remain after
adjusting for self-reported smoking intensity. Thus it remains unclear
if these effects are mediated entirely by smoking behaviour, if they
also involve an increased vulnerability to the harmful effects of
smoking or if there is a smoking-independent effect. The recently
discovered association with exhaled carbon monoxide levels26
suggests aspects of cigarette smoke exposure not captured by
common measures of smoking quantity and thus the residual
associations may still be due to genetic effects on smoking exposure.
Interestingly a potential association (P¼ 6 10 7) has been
reported for serum albumin levels in a large meta-analysis27, a
known biomarker of all-cause mortality after 5-year follow-up28.
Variants in linkage disequilibrium (LD) with the sentinel SNP are
also associated with cotinine29 (the principal metabolite of nicotine),
1-methylurate29 (a major metabolite of theophylline, used to treat
chronic obstructive pulmonary disease), and lathosterol29 (an
indicator of whole body cholesterol synthesis). There is no reported
evidence of sex differentiation in the known associations but we
observe a much stronger effect of rs10519203 for younger paternal
deaths, consistent with the higher prevalence of smoking among men
of that generation30.
The relative importance of frailty genes, affecting the age-
speciﬁc susceptibility to death, versus longevity genes, which
promote long life, has been much debated31. The CHRNA3/5
locus is the ﬁrst true frailty gene to be identiﬁed, as the mortality
of carriers of the risk variant decreases to nearly that of non-
carriers with advancing age. This can be explained by the longer-
lived carriers of the G allele at rs10519203 possessing other
genetic or environmental factors that compensate for the risk (for
example, never smoked). In contrast APOE has a stronger effect
on mortality for the older deaths.
We did not replicate the recently published chromosome 5q33
or FOXO3 associations with survival to 90 years of age6,10 with P
values over 0.02 for 87 SNPs across 400 kb, despite considerable
power to do so. Possible explanations include that these loci
inﬂuence longevity in a way that is diluted when considering
deaths from 40 onwards, or that they are false positive
associations.
In spite of the similar magnitude of effects for CHRNA3/5 and
APOE in our analysis of4190,000 parental deaths, the CHRNA3/
5 association was not seen in the largest published nonagenarian
analyses6,10, probably because the association with death is very
weak after 75 years, and is driven mostly by younger male deaths,
many of which might have already occurred before participation
in the population-based studies analysed.
The adverse effects on lifespan of the two associated loci have
both likely been hidden from natural selection, CHRNA3/5
because its effect is mediated through the modern risk of nicotine
dependence and APOE, because its effect occurs long after child-
bearing age. The absence of evidence for other loci affecting
lifespan (either in terms of more genome-wide signiﬁcant
associations—Fig. 1 or an enrichment of suggestive associations
beyond that expected by chance—Supplementary Fig. 1d), is
difﬁcult to interpret as rarer variants or those with weaker effects
might be discovered in even larger analyses, such as with the
entire UKB sample.
Nonetheless, we have shown that even a trait as complex as
parental lifespan is amenable to GWAS using the power provided
by hundreds of thousands of data points. The two lifespan loci
discovered here both contain very pleiotropic disease suscept-
ibility genes, inﬂuencing risk for multiple disorders that cause
most deaths in the developed world. The major genetic risk
factors for dying appear to represent the sum total of genetic
effects on mortality mediated by the different diseases they
inﬂuence. The large number of parental lifespans analysed
provide robust evidence for large sex- and age-differentiated
effects of both APOE and CHRNA3/5 variants, which merit
further investigation. Thus, whereas parental traits may be of
interest in diverse spheres of biology, lifespan, as the ultimate
trait, beneﬁts more than any other from using the kinship
between offspring and parent to increase power for association.
Methods
Outline. Our study closely followed standard methods for GWAS meta-analysis
studies of a quantitative trait (GWAMA)32, with human lifespan as the phenotype,
with the following exceptions. First, the phenotyped subjects were parents of
participants in UKB. Parental phenotypes were regressed on offspring genotypes, in
effect imputing parent genotype from offspring. The effects measured are thus of
offspring genotype on parental phenotype and the expected allelic doses in the
parental generation are thus half the measured doses (in offspring). Effect estimates
per parental allele are thus twice that of offspring allele, which is what we report
unless otherwise stated. Second, as all subjects were genotyped on only two highly
overlapping arrays, focus was on array, rather than imputed genotypes.
UK Biobank. UKB participants were recruited from the general UK population
across 22 centres between 2006 and 2010 (ref. 7). Subjects were aged 40–69 at
baseline, underwent extensive phenotyping by questionnaire and clinic measure-
ments, and provided a blood sample. All participants gave written informed
consent and the study was approved by the North West Multicentre Research
Ethics Committee. UKB has Human Tissue Authority research tissue bank
approval, meaning separate ethical approvals are not required to use the existing
data. Genotyping is in progress, with a wave 1 public release in June/July 2015.
Data access to UKB was granted under MAF 8304. Phenotypes and genotypes were
downloaded direct from UKB. In total, 502,664 subjects had phenotypic infor-
mation available, of whom 152,732 had been genotyped. Parental ages and whether
they were alive at time of interview were reported in the UKB questionnaire.
Estonian biobank. The Estonian Biobank33 is the population-based biobank of the
Estonian Genome Center at the University of Tartu (EGCUT). A total of 51,380
volunteer participants (aged 18–103) were recruited between 2002 and 2011. The
cohort included B5% of the population from all counties of Estonia. At
recruitment, the participants completed an extensive questionnaire on health,
lifestyle and genealogy and provided a blood sample. A broad informed consent
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enables regular linkage of the data with the Estonian mortality registry providing
accurate data on participants’ mortality and causes of death. As of April 2014, there
were 2,663 mortalities registered in the cohort, with mean follow-up time for the
surviving being 6 years. In total, DNA samples from 416,000 participants have
been genotyped with various genome-wide arrays. In 2011, the subset of
individuals selected to be genotyped with the Illumina OmniExpress chip,
intentionally included 1,200 individuals who had died by that time, as well as 500
women and 250 men who were 80 years old or older at that time. The rest of this
genotyped sample (in total 7,950 subjects after removing close relatives) consists of
random population controls.
Genotyping. UKB participants were genotyped on two slightly different arrays and
quality control was performed by UKBiobank. In brief,B50,000 were genotyped as
part of the UK BiLEVE study using a newly designed array, with the remaining
samples (B100,000) genotyped on an updated version (UK Biobank Axiom array),
both manufactured by Affymetrix (96% of SNPs overlap between the arrays).
Samples were processed and genotyped in batches (used as covariates to control for
confounding due to batch effects). In brief, SNPs or samples with high missingness,
multi-allelic SNPs and SNPs with batchwise departures from Hardy–Weinberg
equilibrium were removed from the data set. Analysis was restricted to the 753,488
autosomal SNPs passing these ﬁlters34. After quality control, genotypes were
available for 152,732 subjects. UKB provided 15 principal components of genetic
relatedness (Biobank ﬁeld id 22,009) and a binary assessment of whether subjects
were genomically British (biobank ﬁeld id 22,006), based on principal components
analysis of their genetic data.
Imputed data were prepared by UKB and used for ﬁne-mapping signals in two
genomic regions of interest. In summary, autosomal phasing was carried out using
a version of SHAPEIT2 (ref. 35) modiﬁed to allow for very large sample sizes.
Imputation was carried out using IMPUTE2 (ref. 36) using the merged UK10K and
1,000 Genomes Phase 3 reference panels to yield higher imputation accuracy of
British haplotypes. The result of the imputation process is a data set with
73,355,667 SNPs, short indels and large structural variants37 . Our analysis for the
Chr15 region (77,826,182–79,826,157 bp) included 54,767 variants and 54,474,
respectively, for the Chr19 region (44,422,982–46,422,870 bp).
The Estonian Biobank genotypes were from the Illumina OmniExpress array. A
total of, 647,357 autosomal SNPs were available for 7,950 subjects. Standard quality
control practices were followed, including removing SNPs and individuals with
high missingness, samples with mismatching genomic and self-declared gender,
ethnic outliers, duplicates, cryptic relatives, SNPs out of Hardy–Weinberg
equilibrium. Imputation followed similar workﬂow to UKB, using SHAPEIT2,
IMPUTE2 and the 1,000 Genomes Phase 3 reference panel.
UKB quality control. For the genotyped subjects, phenotypic quality control
proceeded as follows. Subjects had completed a questionnaire which asked, inter
alia, whether parents were alive or dead, the parents’ ages and whether the subject
was adopted. Parent deaths prior to the age of 40 were excluded to reduce the effect
of accidents and war. Our phenotype was thus survival from the age of 40. Subjects
who were adopted (2,296), whose parents both died before age 40 or for whom no
parental ages/alive status were recorded (3,278), whose parent ages were clearly
invalid (4115; n¼ 2), or had non-useful (small or vague) ethnicity recorded
(7,065) or had a missing covariate (181) were excluded, leaving 139,910 partici-
pants with complete father or mother data for analysis.
Of these, 116,279 were self-identifying British and were assessed as genetically
British by UKB; these were the subjects analysed in the discovery phase.
Supplementary Table 2 presents the mean and maximum parental ages by status
for these subjects.
In the UKB part of the replication phase, we analysed subjects not included in
the discovery phase, that is, subjects who had not self-identiﬁed as ‘British’ or UKB
had determined as not unambiguously genetically British. Self-declared ethnicities
that had fewer than 300 subjects (‘Asian’, ‘Bangladeshi’, ‘black’, ‘mixed’) or were
ambiguous (‘any other’, ‘prefer not to say’, ‘white’), were not analysed. This resulted
in 23,631 subjects across seven sub-populations: self-declared British—but not
unambiguously genomically British 16,218; African 681; Caribbean 962; Chinese
338; Indian 1,245; Irish 3,819; Pakistani 368. More details on the counts of subjects
ﬂowing through quality control are available in Supplementary Table 3.
Association testing. Although our analysis followed the broad strategy of best
practice GWAMA, the unique characteristics of our data set and, to a lesser extent,
trait meant we modiﬁed the design slightly. All subjects were genotyped on only
two, very similar, arrays. This meant we could perform GWAS directly on array
SNPs, without losing the majority of SNPs due to missingness, an issue usually
addressed through imputation. The computational burden of ﬁtting a full Cox
model and GWAS one SNP at a time across all array SNPs was infeasible for
116,279 subjects. So, we ﬁrst calculated Martingale residuals38 for survivorship in
the Cox proportional hazards model (CPHM)39 excluding genotype using the R
package survival and then used PLINK 1.9 (ref. 40) to perform a GWAS scan at
array SNPs for these residuals. Manhattan plots were created in R using the
package qqman41. For the two clearly associated regions, we then created locus
zoom plots using imputed genotypes and the Martingale residuals (the discovery
phase). The top array SNP for mothers and fathers combined in each
unambiguously associated region was then analysed using a full CPHM
simultaneously modelling array genotype and other covariates, allowing us to
determine P values directly and calculate allelic effects on the more natural scales of
hazard ratio and life years (veriﬁcation phase). Finally, the association between the
top array SNPs and lifespan was tested in three other populations (replication
phase).
Association testing was conducted under the following CPHM,
h xð Þ ¼ h0 xð ÞebXþ g1Z1 þ ... þ gkZk ; ð1Þ
with h0(x) being the baseline hazard given the parental age and dead/alive status, X
the non-reference allele count of the marker and Z1,y, Zk the other covariates in
the model: subjects’ (not parental) sex, indicators of assessment centre and
genotyping batch, Townsend deprivation index (a measure of socio-economic
status), and 15 principal components of genetic relatedness for all 152,732
considered together.
Where shown, results for fathers and mothers combined were calculated using
inverse-variance meta-analysis on the log hazard ratios.
In the discovery phase (using unambiguously genetically British), Martingale
residuals of the Cox model (without genotype) were calculated using the R package
‘Survival’. The Martingale residuals38 are deﬁned as,
bMi ¼ di  bL0 tið Þebg1Z1 þ ... þbgkZk ; ð2Þ
where di and ti are the event indicator (1—died, 0—survived at the end of follow-
up) and follow-up time of the ith individual, bg1 . . . bgk are the estimates of the
coefﬁcients of the covariates Z1y Zk in the model from equation (1), omitting the
genetic markers. In case of non-zero b that model bMi should have a linear
association with the marker score Xi. These residuals were subsequently rank-
normal transformed to give a normally distributed survival score for each subject.
These scores were then tested for association with genotype using PLINK. This
process was then repeated but conditioned on the two top SNPs (rs429358 and
rs10519203), to determine if there was evidence of additional allelic effects local to
their regions.
In the veriﬁcation phase the two top SNPs were analysed singly using the full
Cox model (including genotype), in R, to give hazard ratios for additive allelic effect
and with Kaplan–Meier survival curve42 being used to calculate expected lifetime
for each genotype. The bivariate analysis of rs4420638, simultaneously ﬁtted the
three SNPs.
In the replication phase, rs429358 and rs10519203 were analysed under the full
Cox model. In UKB each sub-population was analysed separately (self-declared
British—but not unambiguously genomically British; African, Caribbean, Chinese,
Indian, Irish, Pakistani) for the effect of allele count on log hazard ratio. Results
were combined for UKB non-self-declared British using a two-sided test and
inverse variance meta-analysis.
We performed an enhanced replication in the Estonian Biobank using
participant lifespans that simultaneously tested whether the effects on parental
lifespan translated into an inﬂuence on survival in a prospective cohort. All-cause
mortality was analysed using Cox modelling in 5,196 individuals including 1,499
deaths from ages 40 to 103, over a mean follow-up time of 6 years, using the ﬁrst
three principal components of genetic relatedness as covariates, in addition to the
effect allele count of the sentinel SNPs. Three models were ﬁtted, a sex-stratiﬁed
model and sex-speciﬁc models for males and females. Given the data structure,
where an excess number of mortalities were included in the genotyped set
compared with the full cohort, baseline hazard and survival estimates are not valid,
but hazard ratios are. As a sensitivity analysis, a case–cohort analysis was
performed43, resulting in identical effect estimates and P values.
The replication cohorts’ results (Estonian Biobank, self-declared British and
self-declared non-British) were then combined using inverse variance meta-
analysis.
Finally, for the unambiguously genomically British samples only (the discovery
phase), we looked at the effect of the risk SNPs over two separate age ranges 40–75
and475 (approximately the mean age at death). To do this, the same Cox models
were rerun, but for the ﬁrst age range, upper age was truncated at 75, and subjects
who lived past aged 75 were recorded as survivors. For the second age range, only
subjects who had survived to age 75 were entered into the analysis, survival to age
75 was thus complete, and the analysis only examined survival beyond age 75.
The expected allelic effect of one allele in offspring is 0.5 alleles in parents. This
can be seen, for an allele (A1) with frequency p, because
 if the offspring is homozygous for the other allele (A0), the expected dosage of
A1 in a parent is p (that is, the probability that the non-inherited allele is A1).
 if the offspring is homozygous A1 the expected dosage in the parent is
2 q¼ 1þ p.
 if the offspring is heterozygous, the expected dosage in a parent is the average of
the previous two values.
Measured effects of offspring genotypes, other than the variances explained in
Fig. 1 have therefore all been doubled, to give measurement on the natural scale—
the effect on parents’ lifespan of one allele in parents.
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